Business Development (8)

Challenge: A VC investor asked Alacrita to conduct due diligence on a clinical stage oncology therapeutic company developing a targeted inhibitor that works via the notch pathway. Priority...

Challenge: A government owned investment firm was considering an investment in a small biopharma company developing a therapeutic monoclonal antibody against a novel immuno-oncology target. Alacrita...

Challenge: A transatlantic life science venture capital fund was contemplating investing in advanced plasma product opportunities being developed by a biopharmaceutical company, and needed a reality...

Challenge: A major European venture capital investor needed to analyze the business plan of a novel point-of-care diagnostics company.

Challenge: An early-stage venture fund asked Alacrita to review the opportunity for reinvestment in a biotech developing a novel live biotherapeutic for the treatment of inflammatory bowel disorders...

Challenge: A well-capitalized Swiss pharma company needed a clinical and commercial reality check for a new imaging technology being developed that was under consideration for acquisition.

Challenge: A venture capital investor needed a reality check on a clinical stage cancer biologic prior to a proposed $10m investment with a very short deadline.

Challenge: A major pharmaceutical company asked us for support in the due diligence and assessment of a Phase III in-licensing opportunity. The drug in question had met its primary endpoint in a...

Challenge: A pharma company needed help conducting due diligence on an in-licensing/acquisition candidate for a Phase IIb respiratory drug.

Challenge: A drug discovery company preparing for a forthcoming funding round wanted to update a valuation of the business based on a series of contract research projects and the proprietary value in...

Challenge: A biotech company with a novel oral drug delivery technology platform was looking to out-license its lead asset, a reformulated generic therapeutic in a new, non-opioid pain, indication,...

Challenge: Alacrita was engaged by a strategic investor to conduct initial due diligence on a new EGFR therapeutic strategy in oncology.